Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Statement re Offer for Subscription

10 Jan 2022 12:43

RNS Number : 9606X
Maven Income and Growth VCT 3 PLC
10 January 2022
 

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the Companies)

 

Offers for Subscription - Early Investment Incentive

 

10 January 2022

 

On 20 September 2021, the Companies published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

In the Prospectus, it was stated that all valid applications that were received (together with their relevant application monies) by the deadline of 12.00 noon on 28 January 2022 would be eligible to receive an Early Investment Incentive discount under the Offers. Existing Shareholders (and their spouses or partners) in any of the Maven VCTs, including the Companies, at the time the application was received would benefit from an enhanced rate of discount in recognition of their continued support for the Maven VCTs. The levels of discount to be applied would be:

 

· 1.5% of the application amount for Existing Shareholders; and

· 1.25% of the application amount for New Investors.

 

It was also stated that each Company could, in consultation with Maven Capital Partners UK LLP (Maven) and in their absolute discretion, extend the deadline by which applications must be received to be eligible for the Early Investment Incentive under its Offer.

 

The Board of each Company confirms that the deadline by which applications must be received to be eligible for the Early Investment Incentive under their Company's respective Offer has been extended until close of business on Wednesday 2 February 2022. Furthermore, it is anticipated that both Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Further information

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Downloadable versions of the Prospectus documents are available from the Maven website at: www.mavencp.com/vctoffer.

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFSFLIIILIF
Date   Source Headline
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:18 pmRNSIssue of Equity
2nd Apr 20255:58 pmRNSAnnual Financial Report
1st Apr 20255:05 pmRNSDirectorate Change
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:12 pmRNSDirector/PDMR Shareholding
27th Mar 20251:07 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
18th Mar 20254:10 pmRNSTransaction in Own Shares
14th Mar 202511:58 amRNSUnaudited NAV and Proposed Final Dividend
19th Feb 202510:20 amRNSDirector/PDMR Shareholding
19th Feb 202510:19 amRNSDirector/PDMR Shareholding
19th Feb 202510:18 amRNSDirector/PDMR Shareholding
19th Feb 202510:11 amRNSIssue of Equity
28th Jan 202512:15 pmRNSStatement re Offer for Subscription
28th Jan 202510:42 amRNSIssue of Equity
24th Jan 202511:34 amRNSNet Asset Value(s)
27th Dec 20249:21 amRNSDirector Declaration
10th Dec 20244:08 pmRNSTransaction in Own Shares
26th Nov 20244:20 pmRNSNet Asset Value(s)
14th Nov 20242:55 pmRNSResult of General Meeting
18th Oct 20249:33 amRNSDirector/PDMR Shareholding
18th Oct 20249:29 amRNSIssue of Equity
15th Oct 20249:06 amRNSStatement re Dividend Investment Scheme
27th Sep 20244:31 pmRNSPublication of a Prospectus
18th Sep 202411:09 amRNSHalf-year Report
2nd Sep 20244:55 pmRNSTransaction in Own Shares
23rd Aug 20242:52 pmRNSStatement re NAV and Interim Dividend
24th May 202410:02 amRNSDirector/PDMR Shareholding
24th May 20249:58 amRNSIssue of Equity - Dividend Investment Scheme
15th May 20244:18 pmRNSTransaction in Own Shares
15th May 20242:17 pmRNSNet Asset Value - Dividend Investment Scheme
9th May 20242:35 pmRNSResult of AGM
9th May 20242:28 pmRNSUnaudited Net Asset Value
1st May 202410:08 amRNSIssue of Equity
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:48 pmRNSIssue of Equity
27th Mar 202410:39 amRNSIssue of Equity
25th Mar 202410:14 amRNSStatement re Offer for Subscription
19th Mar 20245:03 pmRNSTransaction in Own Shares
20th Feb 20242:48 pmRNSDividend Declaration
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:10 amRNSIssue of Equity
17th Jan 202410:03 amRNSDirector/PDMR Shareholding
17th Jan 202410:02 amRNSDirector/PDMR Shareholding
17th Jan 20249:58 amRNSIssue of Equity
15th Jan 20244:28 pmRNSUnaudited Net Value Asset
15th Nov 20235:06 pmRNSTransaction in Own Shares
9th Nov 20233:53 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.